Registry of Catheter Intervention in Pulmonary Embolism

Launched by HOSPITAL SAN CARLOS, MADRID · Mar 28, 2024

Keywords

ClinConnect Summary

This clinical trial, titled the "Registry of Catheter Intervention in Pulmonary Embolism," is studying how different catheter-based treatments can help patients with serious cases of pulmonary embolism (PE), which is a blockage in the lungs caused by blood clots. The goal is to understand how safe and effective these treatments are for patients who are at moderate to high risk for complications from PE. The researchers are collecting data from both past patients and those currently being treated to get a comprehensive view of these interventions.

To be eligible for the trial, participants must be adults aged 18 or older, diagnosed with acute pulmonary embolism through imaging tests, and classified as high-risk according to specific medical guidelines. This means they have certain markers indicating a more severe case, like elevated heart stress indicators. If you join the study, you can expect to be part of a registry that tracks your treatment outcomes and experiences. This trial is currently recruiting participants of all genders, and your involvement could help improve treatment options for future patients facing similar health challenges.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • adult patients (aged 18 years old or older)
• • confirmed diagnosis of acute PE (on computed tomography or echocardiogram plus pulmonary angiography)
• • high-risk PE or intermediate-high risk according to ESC risk stratification in the 2019 guidelines (briefly, elevated cardiac biomarkers \[troponin or N-terminal pro-B-type natriuretic peptide\], and right ventricle to left ventricle ratio \> 0.9 \[on computed tomography or echocardiogram\], and PE severity index III to IV or simplified PE severity index=1
• • eligibility for catheter-directed intervention
• Exclusion Criteria:
• • unconfirmed diagnosis of PE
• • undefined risk stratification, and
• • PE with uncertain chronology or beyond seven days of symptom initiation.